SARS-CoV-2 vaccine uptake, perspectives and adverse reactions following vaccination in patients with cancer undergoing treatment
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were developed, tested, and approved in record time. As patients with cancer were excluded from vaccine trials, some patients may be hesitant[1] given unanswered questions around safety and adverse reactions, especially those undergoing treatment. One study conducted among 134 patients receiving immune checkpoint inhibitors (ICI) reported a 81% BNT162b2 vaccine uptake rate with similar rates of acute adverse reactions as reported among healthy individuals, except for higher frequency of myalgias among patients with cancer.[2] Further research is needed by tumor type and treatment in order to better inform clinicians and patients during the vaccine decision-making process.
Annals of Oncology , commentaire en libre accès, 2021